To further underline the potential involvement of adiponectin in the pathogenesis of BC, a meta-analysis has concluded that postmenopausal BC patients had significantly lower serum adiponectin than healthy subjects and that the levels of this adipokine may be used as a predictor to determine the patients that require more aggressive treatments and for survival rates [92]. This evidence concerns the gene ADIPOQ and breast cancer.